Mesenchymal Stem Cells Ameliorate Podocyte Injury and Proteinuria in a Type 1 Diabetic Nephropathy Rat Model

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 4, 2013, Pages 538-546

  Wang, Shuai ^a,b   Li, Yi ^a   Zhao, Jinghong ^a   Zhang, Jingbo ^a   Huang, Yunjian ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

Bone morphogenetic protein 7; Cell therapy; Diabetic nephropathy; Mesenchymal stem cells; Podocyte injury; Proteinuria

Indexed keywords

ALBUMIN; CREATININE; GREEN FLUORESCENT PROTEIN; NEPHRIN; OSTEOGENIC PROTEIN 1; PODOCIN; STREPTOZOCIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL DAMAGE; CELL SURVIVAL; CELL TRACKING; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; FOOT; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; IMMUNOFLUORESCENCE; IN VIVO STUDY; KIDNEY MASS; MALE; MESENCHYMAL STEM CELL; NONHUMAN; PODOCYTE; PROTEINURIA; RAT; RENAL ARTERY; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BONE MORPHOGENETIC PROTEIN 7; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GENE EXPRESSION; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MALE; MEMBRANE PROTEINS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; PODOCYTES; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875540692     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.01.001     Document Type: Article

References (53)

1. Molitch M.E., DeFronzo R.A., Franz M.J., et al. Nephropathy in diabetes. Diabetes Care 2004, 27(Suppl 1):S79-S83.
2. Steffes M.W., Schmidt D., McCrery R., Basgen J.M. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 2001, 59:2104-2113.
3. Ziyadeh F.N., Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008, 4:39-45.
4. Dalla Vestra M., Masiero A., Roiter A.M., et al. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003, 52:1031-1035.
5. White K.E., Bilous R.W. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant 2004, 19:1437-1440.
6. Togel F., Westenfelder C. Adult bone marrow-derived stem cells for organ regeneration and repair. Dev Dyn 2007, 236:3321-3331.
7. Ezquer F.E., Ezquer M.E., Parrau D.B., et al. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant 2008, 14:631-640.
8. Lee R.H., Seo M.J., Reger R.L., et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci U S A 2006, 103:17438-17443.
9. Jiang T.S., Cai L., Ji W.Y., et al. Reconstruction of the corneal epithelium with induced marrow mesenchymal stem cells in rats. Mol Vis 2010, 16:1304-1316.
10. Mafi P., Hindocha S., Mafi R., et al. Adult mesenchymal stem cells and cell surface characterization - a systematic review of the literature. Open Orthop J 2011, 5:253-260.
11. Kunter U., Rong S., Djuric Z., et al. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006, 17:2202-2212.
12. Lee E.A., Seo J.Y., Jiang Z., et al. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Kidney Int 2005, 67:1762-1771.
13. Thallas-Bonke V., Thorpe S.R., Coughlan M.T., et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008, 57:460-469.
14. Macedo C.S., Lerco M.M., Capelletti S.M., et al. Reduction of podocytes number in late diabetic alloxan nephropathy: prevention by glycemic control. Acta Cir Bras 2007, 22:337-341.
15. van den Berg J.G., van den Bergh Weerman M.A., Assmann K.J., et al. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 2004, 66:1901-1906.
16. Gundersen H.J., Seefeldt T., Osterby R. Glomerular epithelial foot processes in normal man and rats. Distribution of true width and its intra- and inter-individual variation. Cell Tissue Res 1980, 205:147-155.
17. Ma J., Matsusaka T., Yang H.C., et al. Induction of podocyte-derived VEGF ameliorates podocyte injury and subsequent abnormal glomerular development caused by puromycin aminonucleoside. Pediatr Res 2011, 70:83-89.
18. Mitu G.M., Wang S., Hirschberg R. BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am J Physiol Renal Physiol 2007, 293:F1641-F1648.
19. Ninichuk V., Gross O., Segerer S., et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int 2006, 70:121-129.
20. Neshati Z., Matin M.M., Bahrami A.R., Moghimi A. Differentiation of mesenchymal stem cells to insulin-producing cells and their impact on type 1 diabetic rats. J Physiol Biochem 2010, 66:181-187.
21. Sun Y., Chen L., Hou X.G., et al. Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro. Chin Med J (Engl) 2007, 120:771-776.
22. Huls M., Russel F.G., Masereeuw R. Insights into the role of bone marrow-derived stem cells in renal repair. Kidney Blood Press Res 2008, 31:104-110.
23. Morigi M., Imberti B., Zoja C., et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004, 15:1794-1804.
24. Asanuma H., Meldrum D.R., Meldrum K.K. Therapeutic applications of mesenchymal stem cells to repair kidney injury. J Urol 2010, 184:26-33.
25. Meirelles Lda S., Fontes A.M., Covas D.T., Caplan A.I. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009, 20:419-427.
26. Ezquer F., Ezquer M., Simon V., et al. Endovenous administration of bone-marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice. Biol Blood Marrow Transplant 2009, 15:1354-1365.
27. Morigi M., Introna M., Imberti B., et al. Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 2008, 26:2075-2082.
28. Semedo P., Correa-Costa M., Antonio Cenedeze M., et al. Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model. Stem Cells 2009, 27:3063-3073.
29. Walczak P., Zhang J., Gilad A.A., et al. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke 2008, 39:1569-1574.
30. Mouiseddine M., Francois S., Souidi M., Chapel A. Intravenous human mesenchymal stem cells transplantation in NOD/SCID mice preserve liver integrity of irradiation damage. Methods Mol Biol 2012, 826:179-188.
31. Schrepfer S., Deuse T., Reichenspurner H., et al. Stem cell transplantation: the lung barrier. Transplant Proc 2007, 39:573-576.
32. Zonta S., De Martino M., Bedino G., et al. Which is the most suitable and effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplantation: endovenous or arterial?. Transplant Proc 2010, 42:1336-1340.
33. Kunter U., Rong S., Boor P., et al. Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J Am Soc Nephrol 2007, 18:1754-1764.
34. Ho J.H., Tseng T.C., Ma W.H., et al. Multiple intravenous transplantations of mesenchymal stem cells effectively restore long-term blood glucose homeostasis by hepatic engraftment and beta cell differentiation in streptozosin-induced diabetic mice. Cell Transplant 2012, 21:997-1009.
35. Neumann K., Endres M., Ringe J., et al. BMP7 promotes adipogenic but not osteo-/chondrogenic differentiation of adult human bone marrow-derived stem cells in high-density micro-mass culture. J Cell Biochem 2007, 102:626-637.
36. Yoo J.H., Park C., Jung D.I., et al. In vivo cell tracking of canine allogenic mesenchymal stem cells administration via renal arterial catheterization and physiopathological effects on the kidney in two healthy dogs. J Vet Med Sci 2011, 73:269-274.
37. Rees D.A., Alcolado J.C. Animal models of diabetes mellitus. Diabet Med 2005, 22:359-370.
38. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008, 51:216-226.
39. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001, 50:537-546.
40. Menini S., Iacobini C., Oddi G., et al. Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin-induced diabetes mellitus: role in the development of diabetic glomerular disease. Diabetologia 2007, 50:2591-2599.
41. Barutta F., Corbelli A., Mastrocola R., et al. Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes 2010, 59:1046-1054.
42. Sohn E., Kim J., Kim C.S., et al. Extract of the aerial parts of Aster koraiensis reduced development of diabetic nephropathy via anti-apoptosis of podocytes in streptozotocin-induced diabetic rats. Biochem Biophys Res Commun 2010, 391:733-738.
43. Saleem M.A. Biology of the human podocyte. Nephron Exp Nephrol 2003, 95:e87-e92.
44. Kawachi H., Miyauchi N., Suzuki K., et al. Role of podocyte slit diaphragm as a filtration barrier. Nephrology (Carlton) 2006, 11:274-281.
45. Ihalmo P., Wessman M., Kaunisto M.A., et al. Association analysis of podocyte slit diaphragm genes as candidates for diabetic nephropathy. Diabetologia 2008, 51:86-90.
46. White K.E. Research into the glomerular podocyte-is it relevant to diabetic nephropathy?. Diabet Med 2006, 23:715-719.
47. Kerjaschki D. Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 2001, 108:1583-1587.
48. Masereeuw R. Contribution of bone marrow-derived cells in renal repair after acute kidney injury. Minerva Urol Nefrol 2009, 61:373-384.
49. Togel F., Hu Z., Weiss K., et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005, 289:F31-F42.
50. Togel F., Weiss K., Yang Y., et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007, 292:F1626-F1635.
51. De Petris L., Hruska K.A., Chiechio S., Liapis H. Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrol Dial Transplant 2007, 22:3442-3450.
52. Wang S., de Caestecker M., Kopp J., et al. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006, 17:2504-2512.
53. Prodromidi E.I., Poulsom R., Jeffery R., et al. Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells 2006, 24:2448-2455.